[Blood transfusions and blood substitutes].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
To make stroma-free hemoglobin (SFHb) capable of carrying oxygen satisfactorily in vivo it is necessary both to improve its intravascular persistence and to reduce its affinity for oxygen. The method used up to now has consisted of chemical modification of SFHb to lower its oxygen affinity (fixation of permanent effector inside the phosphate binding site or intramolecular cross-linking of the deoxy form of SFHb), then polymerization or substitution with polymers. We have designed new functionalized polymers (from dextran and polyoxyethylene), capable of mimicking the effect of the natural intraerythrocyte effector, 2,3-disphosphoglycerate, i.e. of decreasing its affinity for oxygen, and we have linked these polymers chemically to oxyHb. All the resulting conjugates have lower oxygen affinity than SFHb and, when injected into rats, do not lead to hemoglobinuria. Preliminary in vivo tests also showed that these conjugates possess no acute toxicity. Further experiments with rats are now under way (60% and 80% hemorrhagic shocks) with the aim of evaluating whether these new products can be regarded as potential candidates for blood substitution.
Explore the source record for details and available documents.
Explore the source record for details and available documents.